Ilias Houda

490 total citations
13 papers, 141 citations indexed

About

Ilias Houda is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ilias Houda has authored 13 papers receiving a total of 141 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ilias Houda's work include Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Ilias Houda is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Ilias Houda collaborates with scholars based in Netherlands, United Kingdom and United States. Ilias Houda's co-authors include Idris Bahce, Sayed M.S. Hashemi, Joris D. Veltman, Marieke F. Fransen, Teodora Radonic, Laurence Crombag, Erik Thunnissen, Johannes M. A. Daniels, Anna-Larissa N. Niemeijer and Chris Dickhoff and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

Ilias Houda

13 papers receiving 141 citations

Peers

Ilias Houda

ONCOL

PRM

IMMUN

Karim Amrane France

Ornella Cantale Italy

Luis D. Mejías Spain

Minori Koshiji Rosales United States

Kristiina Ojamaa Estonia

Marinela Augustin Germany

N. Girard France

Patricia Iranzo Spain

Cristina Viaplana Spain

Karim Amrane France

Ilias Houda

105 ×1.0

ONCOL

70 ×0.9

PRM

26 ×1.0

IMMUN

19 ×1.2

11 ×0.7

Citations per year, relative to Ilias Houda Ilias Houda (= 1×) peers Karim Amrane

Countries citing papers authored by Ilias Houda

Since Specialization

Citations

This map shows the geographic impact of Ilias Houda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilias Houda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilias Houda more than expected).

Fields of papers citing papers by Ilias Houda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilias Houda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilias Houda. The network helps show where Ilias Houda may publish in the future.

Co-authorship network of co-authors of Ilias Houda

This figure shows the co-authorship network connecting the top 25 collaborators of Ilias Houda. A scholar is included among the top collaborators of Ilias Houda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilias Houda. Ilias Houda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Bahce, Idris, Chris Dickhoff, Famke L. Schneiders, et al.. (2024). Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study. Journal for ImmunoTherapy of Cancer. 12(9). e009799–e009799. 5 indexed citations

Houda, Ilias, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.. (2024). New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe. The Lancet Regional Health - Europe. 38. 100840–100840. 18 indexed citations

Houda, Ilias, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.. (2024). Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective. The Lancet Regional Health - Europe. 38. 100841–100841. 17 indexed citations

Houda, Ilias, Idris Bahce, Chris Dickhoff, et al.. (2023). OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 18(11). S55–S56. 8 indexed citations

Hashemi, Sayed M.S., Ilias Houda, Joris D. Veltman, et al.. (2023). Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC. JTO Clinical and Research Reports. 4(9). 100532–100532. 24 indexed citations

Heineman, David J., Famke L. Schneiders, Ilias Houda, et al.. (2023). OA06.04 Surgery after Neoadjuvant Immuno-Chemoradiotherapy in (Borderline) Resectable NSCLC: Results from the INCREASE Trial. Journal of Thoracic Oncology. 18(11). S56–S57. 4 indexed citations

Houda, Ilias, Sayed M.S. Hashemi, Johannes M. A. Daniels, et al.. (2023). 1445P A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis. Annals of Oncology. 34. S821–S822. 1 indexed citations

Rakaee, Mehrdad, Elio Adib, Biagio Ricciuti, et al.. (2023). Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non–small-cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). 9132–9132. 2 indexed citations

Bahce, Idris, Famke L. Schneiders, Sayed M.S. Hashemi, et al.. (2022). 1020P Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study. Annals of Oncology. 33. S1021–S1021. 1 indexed citations

10.

Rakaee, Mehrdad, Elio Adib, Biagio Ricciuti, et al.. (2022). Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC.. Journal of Clinical Oncology. 40(16_suppl). 9065–9065. 5 indexed citations

11.

Rakaee, Mehrdad, Elio Adib, Biagio Ricciuti, et al.. (2022). Digital quantification of lymphocytic infiltration on routine H&E images and immunotherapy response in non–small cell lung cancer.. Journal of Clinical Oncology. 40(16_suppl). 9066–9066. 1 indexed citations

12.

Hashemi, Sayed M.S., Marieke F. Fransen, Anna-Larissa N. Niemeijer, et al.. (2021). Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study. Lung Cancer. 153. 81–89. 49 indexed citations

13.

Hashemi, Sayed M.S., Jos W. R. Twisk, Ilias Houda, et al.. (2021). The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors. Lung Cancer. 162. 36–41. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact